Webinar Title: Fall and Fracture Findings in Patients receiving NUPLAZID^® (pimavanserin) for Parkinson’s Disease Psychosis.

Webinar Description: This session reviews the clinical burden of falls and fractures among patients with Parkinson’s disease psychosis (PDP), particularly in long-term care settings. It presents real-world, claims-based evidence comparing outcomes among patients treated with pimavanserin versus other atypical antipsychotics.

Attendees will explore study design, including matched cohort methodology and key outcome measures for falls and fracture risk. The session highlights observed differences in fall and fracture outcomes across treatment groups while emphasizing appropriate interpretation of observational data. Discussion will focus on clinical context, CMS quality implications, and practical considerations for managing fall risk in PDP populations.

Learning Objectives: 

• Describe the clinical burden and risk factors for falls and fractures in patients with Parkinson’s disease psychosis, particularly in long-term care populations
• Explain the design and methodology of real-world, claims-based studies evaluating fall and fracture outcomes in PDP patients
• Interpret observational comparative data on fall and fracture risk across treatment groups, including key limitations and appropriate clinical context

Registration Link Coming Soon!

✔ NAB Approved for 1 CE (TBD)

Pricing
Members: Complimentary
Non-Members: $TBD